Episode Details
Back to Episodes
Week in Review | Lilly's Retatrutide Lawsuits: Enforcing a Drug Nobody Has Approved
Published 1 month ago
Description
Eli Lilly filed six lawsuits over black-market retatrutide and has referred more than 200 sellers to regulators — before it has even filed for approval. Plus Bristol Myers Squibb's accelerated approval of Zenbexus (iberdomide) with Darzalex in multiple myeloma on a 41% versus 21% MRD-negative complete response, Taiho and Cullinan's early Phase 3 unblinding for zipalertinib in EGFR exon 20 lung cancer, Silence Therapeutics' 88% versus 19% divesiran result in polycythemia vera, and Rhythm's UK expansion for IMCIVREE in acquired hypothalamic obesity. Visit us at thepharmacloseout.com.